{"text_format":"1","workbook":"xlsx","n_sheets":1,"sheets":["Q1-2024"],"not_rendered":{"charts":0,"images":0,"macros":1,"external_links":0,"defined_names":2,"comments":0,"pivot_tables":0},"unopened":[],"bounds":{"document_bytes":16777216,"sheet_cells":100000,"rows_first":2000,"rows_last":500,"rows_between":2000,"halvings":0,"cell_chars":16384,"cell_head_chars":4096},"cells_cut":0,"cells_raw":0,"read":"whole","date_system":"1900"}

{"sheet":"Q1-2024","index":0,"n_rows":113,"n_cols":5,"rows_kept":113,"cut":false,"hidden":false,"merged":[]}
["Therapeutic area","Project ","Phase ","NCT number ","Title"]
["Immunology & Iinflammation","amlitelimab \n(anti-OX40L mAb)","\nPhase 2\n","NCT05492578","Long-Term Safety and Efficacy Evaluation of Amlitelimab in Participants of Previous Amlitelimab Moderate to Severe Atopic Dermatitis Clinical Trials"]
["Immunology & Iinflammation","amlitelimab \n(anti-OX40L mAb)","\nPhase 2\n","NCT06015308","A Study to Investigate Vaccine Responses in Subcutaneous Amlitelimab Treated Atopic Dermatitis Participants Aged 18 Years and Older Compared With Placebo"]
["Immunology & Iinflammation","amlitelimab \n(anti-OX40L mAb)","\nPhase 2\n","NCT05131477","Study Testing Response Effect of KY1005 Against Moderate-to-Severe Atopic Dermatitis, The STREAM-AD Study"]
["Immunology & Iinflammation","amlitelimab \n(anti-OX40L mAb)","\nPhase 2\n","NCT05769777","Open Label, Long-term Study Evaluating Safety and Efficacy of Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Atopic Dermatitis"]
["Immunology & Iinflammation","amlitelimab \n(anti-OX40L mAb)","\nPhase 3\n","NCT06130566","A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab Monotherapy Compared With Placebo in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis (COAST 1)"]
["Immunology & Iinflammation","amlitelimab \n(anti-OX40L mAb)","Phase 3","NCT06181435","A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab Monotherapy Compared With Placebo in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis (COAST 2)"]
["Immunology & Iinflammation","amlitelimab \n(anti-OX40L mAb)","Phase 3","NCT06224348","A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis on Background Topical Corticosteroids (SHORE)"]
["Immunology & Iinflammation","amlitelimab \n(anti-OX40L mAb)","Phase 3","NCT06241118","A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab on Background Topical Corticosteroids Therapy in Participants Aged 12 Years and Older With Moderate-to-severe AD Who Have Had an Inadequate Response to Prior Biologic Therapy or an Oral JAK Inhibitor (AQUA)"]
["Immunology & Iinflammation","amlitelimab \n(anti-OX40L mAb)","\nPhase 2\n","NCT06118099","Proof-of-concept Study Evaluating Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Hidradenitis Suppurativa"]
["Immunology & Iinflammation","amlitelimab \n(anti-OX40L mAb)","\nPhase 2\n","NCT05421598","Dose Ranging Study of Amlitelimab in Adult Participants With Moderate-to-severe Asthma"]
["Immunology & Iinflammation","amlitelimab \n(anti-OX40L mAb)","\nPhase 2\n","NCT06033833","Long-term Safety and Efficacy Evaluation of Subcutaneous Amlitelimab in Adult\nParticipants With Moderatetosevere Asthma Who Completed Treatment Period of Previous Amlitelimab Asthma Clinical Study"]
["Immunology & Iinflammation","amlitelimab \n(anti-OX40L mAb)","\nPhase 2\n","NCT06280391","A Proof-of-Concept Study to Assess the Efficacy, Safety and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Non-cystic Fibrosis Bronchiectasis"]
["Immunology & Iinflammation","frexalimab \n(anti-CD40L mAb)","\nPhase 2\n","NCT05039840","Efficacy and Safety of SAR441344 in the Treatment of Systemic Lupus Erythematosus"]
["Immunology & Iinflammation","frexalimab \n(anti-CD40L mAb)","\nPhase 2\n","NCT06111586","FrexalimAB in Preservation of Endogenous insULIN Secretion Compared to Placebo in adUlts and Adolescents on Top of inSulin Therapy (FABULINUS)"]
["Immunology & Iinflammation","SAR441566 \n(TNFR1 signaling inhibitor)","\nPhase 2\n","NCT06073119","A Study to Evaluate Efficacy and Safety of SAR441566 in Adults With Plaque Psoriasis"]
["Immunology & Iinflammation","SAR441566 \n(TNFR1 signaling inhibitor)","\nPhase 2\n","NCT06073093","A Study to Evaluate SAR441566 Efficacy and Safety in Adults With Rheumatoid Arthritis"]
["Immunology & Iinflammation","itepekimab \n(anti-IL33 mAb)","\nPhase 3\n","NCT04751487","Study to Assess the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/ Itepekimab in Chronic Obstructive Pulmonary Disease (COPD) (AERIFY-2)"]
["Immunology & Iinflammation","itepekimab \n(anti-IL33 mAb)","\nPhase 3\n","NCT04701983","Study to Assess the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/ Itepekimab in Chronic Obstructive Pulmonary Disease (COPD)"]
["Immunology & Iinflammation","itepekimab \n(anti-IL33 mAb)","\nPhase 2\n","NCT05326412","Mechanistic Study of the Effect of Itepekimab on Airway Inflammation in Patients With COPD"]
["Immunology & Iinflammation","rilzabrutinib \n(BTK inhibitor)","\nPhase 2\n","NCT04520451","Open Label Two-Arm Study to Evaluate Rilzabrutinib in IgG4-Related Disease Patients"]
["Immunology & Iinflammation","rilzabrutinib \n(BTK inhibitor)","\nPhase 2\n","NCT05107115","Rilzabrutinib for the Treatment of Chronic Spontaneous Urticaria in Patients Who Remain Symptomatic Despite the Use of H1 Antihistamine"]
["Immunology & Iinflammation","rilzabrutinib \n(BTK inhibitor)","\nPhase 2\n","NCT05104892","Proof of Concept Study of Rilzabrutinib in Adult Participants With Moderate-to-severe Asthma"]
["Immunology & Iinflammation","lunsekimig \n(anti-IL13/TSLP Nanobody VHH)","\nPhase 2\n","NCT06102005","Dose Ranging Study of SAR443765 Compared With Placebo-control in Adult Participants With Moderate to Severe Asthma"]
["Immunology & Iinflammation","SAR447189 \n(anti-TL1A mAb)","\nPhase 2\n","NCT05499130","A Study to Test the Effect of TEV-48574 in Moderate to Severe Ulcerative Colitis or Crohn's Disease"]
["Immunology & Iinflammation","SAR447189 \n(anti-TL1A mAb)","\nPhase 2\n","NCT05668013","A Study to Evaluate the Long-Term Effect of TEV-48574 in Moderate to Severe Ulcerative Colitis or Crohn's Disease"]
["Immunology & Iinflammation","SAR444656 \n(IRAK4 degrader)","\nPhase 2\n","NCT06058156","Phase 2 Study of SAR444656 in Adult Participants With Moderate to Severe Atopic Dermatitis"]
["Immunology & Iinflammation","SAR444656 \n(IRAK4 degrader)","\nPhase 2\n","NCT06028230","A Phase 2 Study to Evaluate the Efficacy and Safety of SAR444656 Compared With Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa"]
["Immunology & Iinflammation","Dupixent \n(anti-IL4/IL13 mAb) ","\nPhase 3\n","NCT04456673","Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate to Severe COPD With Type 2 Inflammation"]
["Immunology & Iinflammation","Dupixent \n(anti-IL4/IL13 mAb) ","\n• Phase 2\n• Phase 3\n","NCT04206553","A Study to Evaluate the Efficacy and Safety of Dupilumab in Adult Patients With Bullous Pemphigoid"]
["Immunology & Iinflammation","Dupixent \n(anti-IL4/IL13 mAb) ","\nPhase 3\n","NCT04180488","Dupilumab for the Treatment of Chronic Spontaneous Urticaria in Patients Who Remain Symptomatic Despite the Use of H1 Antihistamine and Who Are naïve to, Intolerant of, or Incomplete Responders to Omalizumab (LIBERTY-CSU CUPID)"]
["Immunology & Iinflammation","Dupixent \n(anti-IL4/IL13 mAb) ","\nPhase 3\n","NCT03560466","Assessment of the Safety and Efficacy of Dupilumab in Children With Asthma (Liberty Asthma Excursion)"]
["Immunology & Iinflammation","Dupixent \n(anti-IL4/IL13 mAb) ","\nPhase 3\n","NCT02612454","Study to Assess the Long-term Safety of Dupilumab Administered in Participants #6 Months to <18 Years of Age With Atopic Dermatitis (AD)"]
["Immunology & Iinflammation","Dupixent \n(anti-IL4/IL13 mAb) ","\nPhase 3\n","NCT05526521","A Study to Investigate the Pharmacokinetics and Safety of Dupilumab in Participants\n#2 Years to <12 Years of Age With Uncontrolled Chronic Spontaneous Urticaria (CSU) (LIBERTY-CSU CUPIDKids)"]
["Immunology & Iinflammation","Dupixent \n(anti-IL4/IL13 mAb) ","\n• Phase 2\n• Phase 3\n","NCT05831176","A Trial to Learn if Dupilumab is Safe for and Helps Adult and Adolescent Participants With Eosinophilic Gastritis With or Without Eosinophilic Duodenitis"]
["Immunology & Iinflammation","Dupixent \n(anti-IL4/IL13 mAb) ","\nPhase 3\n","NCT05263206","Efficacy and Safety of Subcutaneous Dupilumab for the Treatment of Adult Participants With Chronic Pruritus of Unknown Origin (CPUO) (LIBERTY-CPUO- CHIC)"]
["Immunology & Iinflammation","Dupixent \n(anti-IL4/IL13 mAb) ","\nPhase 2\n","NCT05731128","A Study to Investigate the Efficacy and Safety of Dupilumab Therapy Compared With Placebo in Participants Aged #18 Years With Moderately to Severely Active Ulcerative Colitis With an Eosinophilic Phenotype (LIBERTY-UC SUCCEED (Study in UC for Clinical Efficacy Evaluation of Dupilumab))"]
["Immunology & Iinflammation","Tzield \n(anti-CD3 mAb )","\nPhase 4\n","NCT05757713","Teplizumab in Pediatric Stage 2 Type 1 Diabetes"]
["Immunology & Iinflammation","Tzield \n(anti-CD3 mAb )","Observational","NCT04598893","Recent-Onset Type 1 Diabetes Extension Study Evaluating the Long-Term Safety of Teplizumab"]
["Immunology & Iinflammation","Tzield \n(anti-CD3 mAb )","\nPhase 2\n","NCT04270942","At-Risk for Type 1 Diabetes Extension Study"]
["Immunology & Iinflammation","Rezurock \n(ROCK2 inhibitor)","\nPhase 3\n","NCT06082037","A Study to Test How Effective Belumosudil Tablets Are for Treating Adult Participants With Chronic Lung Allograft Dysfunction"]
["Immunology & Iinflammation","eclitasertib \n(RIPK1 inhibitor)","\nPhase 2\n","NCT05588843","Dose-finding Study of SAR443122 in Adult Participants With Ulcerative Colitis"]
["Immunology & Iinflammation","riliprubart\n(Complement C1S inhibitor)","\nPhase 2\n","NCT05156710","BIVV020 (SAR445088) n Prevention and Treatment of Antibody-mediated Rejection (AMR)"]
["Immunology & Iinflammation","SAR442970 \n(anti-TNFa/OX40L Nanobody VHH)","\nPhase 2\n","NCT05849922","A Study to Test the Efficacy and Safety\nof SAR442970 in Adults With Hidradenitis Suppurativa"]
["Immunology & Iinflammation","SAR444336 \n(Non-beta IL2 Synthorin molecule)","\nPhase 1\n","NCT05876767","Tolerability, Pharmacokinetics and Pharmacodynamics of Ascending Single and Repeated Doses of SAR444336 in Healthy Adult Participants"]
["Neuro-inflammation","frexalimab \n(anti-CD40L mAb)","\nPhase 3\n","NCT06141473","Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis"]
["Neuro-inflammation","frexalimab \n(anti-CD40L mAb)","\nPhase 2\n","NCT04879628","Proof-of-concept Study for SAR441344 (Frexalimab) in Relapsing Multiple Sclerosis"]
["Neuro-inflammation","frexalimab \n(anti-CD40L mAb)","\nPhase 3\n","NCT06141486","Efficacy and Safety Study of Frexalimab (SAR441344) in Adults With Nonrelapsing Secondary Progressive Multiple Sclerosis"]
["Neuro-inflammation","tolebrutinub \n(BTK inhibitor)","\nPhase 3\n","NCT04458051","Primary Progressive Multiple Sclerosis (PPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (PERSEUS)"]
["Neuro-inflammation","tolebrutinub \n(BTK inhibitor)","\nPhase 3\n","NCT04411641","Nonrelapsing Secondary Progressive Multiple Sclerosis (NRSPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168)"]
["Neuro-inflammation","tolebrutinub \n(BTK inhibitor)","\nPhase 3\n","NCT04410991","Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168)"]
["Neuro-inflammation","tolebrutinub \n(BTK inhibitor)","\nPhase 3\n","NCT04410978","Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168)"]
["Neuro-inflammation","tolebrutinub \n(BTK inhibitor)","\nPhase 2\n","NCT03996291","Long Term Safety and Efficacy Study of Tolebrutinib (SAR442168) in Participants With Relapsing Multiple Sclerosis"]
["Neuro-inflammation","SAR443820 \n(RIPK1 inhibitor central)","\nPhase 2\n","NCT05630547","A Study to Evaluate the Effect of SAR443820 on Serum Neurofilament Levels in Male and Female Adult Participants With Multiple Sclerosis"]
["Neuro-inflammation","riliprubart\n(Complement C1S inhibitor)","\nPhase 2\n","NCT04658472","Proof-of-concept Study for SAR445088 in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)"]
["Neuro-inflammation","SAR446159 \n(anti-Synuclein/IGF1R mAb)","\nPhase 1\n","NCT05756920","This is a Study to Evaluate the Safety, Tolerability, PK and PD of IV Administered ABL301 in Healthy Adult Participants"]
["Rare diseases","rilzabrutinib \n(BTK inhibitor)","\nPhase 3\n","NCT04562766","Study to Evaluate Rilzabrutinib in Adults and Adolescents With Persistent or Chronic Immune Thrombocytopenia (ITP)"]
["Rare diseases","rilzabrutinib \n(BTK inhibitor)","\n• Phase 1\n• Phase 2\n","NCT03395210","A Study of Rilzabrutinib in Adult Patients With Immune Thrombocytopenia (ITP)"]
["Rare diseases","rilzabrutinib \n(BTK inhibitor)","\nPhase 2\n","NCT05002777","Efficacy, Safety and Pharmacokinetics of Rilzabrutinib in Patients With Warm Autoimmune Hemolytic Anemia (wAIHA)"]
["Rare diseases","fitusiran \n(RNAi targeting anti-thrombin)  ","\n• Phase 2\n• Phase 3\n","NCT03974113","Fitusiran Prophylaxis in Male Pediatric Subjects Aged 1 to Less Than 12 Years With Hemophilia A or B"]
["Rare diseases","fitusiran \n(RNAi targeting anti-thrombin)  ","\nPhase 3\n","NCT03754790","Long-term Safety and Efficacy Study of Fitusiran in Patients With Hemophilia A or B, With or Without Inhibitory Antibodies to Factor VIII or IX"]
["Rare diseases","venglustat \n(oral GCS inhibitor) ","\nPhase 3\n","NCT05280548","A Study to Evaluate the Effect of Venglustat Tablets on Left Ventricular Mass Index in Male and Female Adult Participants With Fabry Disease"]
["Rare diseases","venglustat \n(oral GCS inhibitor) ","\nPhase 3\n","NCT05206773","A Study to Evaluate the Effect of Venglustat Tablets on Neuropathic and Abdominal Pain in Male and Female Participants #16 Years of Age With Fabry Disease"]
["Rare diseases","venglustat \n(oral GCS inhibitor) ","\nPhase 3\n","NCT05222906","Study to Evaluate the Efficacy and Safety\nof Venglustat in Adult and Pediatric Patients With Gaucher Disease Type 3"]
["Rare diseases","venglustat \n(oral GCS inhibitor) ","\nPhase 2\n","NCT02843035","Venglustat in Combination With Cerezyme in Adult Patients With Gaucher Disease Type 3 With Venglustat Monotherapy Extension"]
["Rare diseases","Nexviazyme \n(Enzyme Replacement Therapy - GAA) ","\nPhase 2\n","NCT03019406","A Study to Assess Safety and Efficacy of Avalglucosidase Alfa Administered Every Other Week in Pediatric Patients With Infantile-onset Pompe Disease Previously Treated With Alglucosidase Alfa"]
["Rare diseases","SAR442501 \n(anti-FGFR3 Ab)","\nPhase 2\n","NCT06067425","Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of SAR442501 in Pediatric Participants With Achondroplasia"]
["Rare diseases","SAR444836 \n(PAH replacement AAV-based gene therapy)","\n• Phase 1\n• Phase 2\n","NCT05972629","A Phase 1/Phase 2 Open-label Study to Evaluate the Safety, Tolerability, and Efficacy of a Single Intravenous Administration of SAR444836 in Adult Participants With Phenylketonuria"]
["Rare diseases","SAR439459 \n(anti-TGFb mAb)","\nPhase 1\n","NCT05231668","Single Ascending Dose Study of SAR439459 in Adults With Osteogenesis Imperfecta (OI)"]
["Rare diseases","riliprubart\n(Complement C1S inhibitor)","\nPhase 1\n","NCT04802057","Safety and Tolerability Study in Adults With Cold Agglutinin Disease Previously Treated With SAR445088 or Never Treated With SAR445088"]
["Oncology","Sarclisa \n(anti-CD38 mAb)","\nPhase 3\n","NCT04270409","A Phase 3 Randomized, Open-label, Multicenter Study of Isatuximab (SAR650984) in Combination With Lenalidomide and Dexamethasone Versus Lenalidomide and Dexamethasone in Patients With High-risk Smoldering Multiple Myeloma"]
["Oncology","Sarclisa \n(anti-CD38 mAb)","\nPhase 1\n","NCT04045795","Multi-center, Open-label, Phase 1b Study in Patients With Relapsed/Refractory Multiple Myeloma (RRMM)"]
["Oncology","Sarclisa \n(anti-CD38 mAb)","\nPhase 3\n","NCT03617731","Trial on the Effect of Isatuximab to Lenalidomide/Bortezomib/Dexamethasone (RVd) Induction and Lenalidomide Maintenance in Patients With Newly Diagnosed Myeloma (GMMG HD7)"]
["Oncology","Sarclisa \n(anti-CD38 mAb)","\nPhase 3\n","NCT03319667","Clinical Benefit of SAR650984, Bortezomib, Lenalidomide and Dexamethasone Combination in NDMM Patients Not Eligible for Transplant"]
["Oncology","Sarclisa \n(anti-CD38 mAb)","\nPhase 3\n","NCT03275285","Multinational Clinical Study Comparing Isatuximab, Carfilzomib And Dexamethasone To Carfilzomib And Dexamethasone In Relapse And/Or Refractory Multiple Myeloma Patients"]
["Oncology","Sarclisa \n(anti-CD38 mAb)","\nPhase 3\n","NCT02990338","Multinational Clinical Study Comparing Isatuximab, Pomalidomide, and Dexamethasone to Pomalidomide and Dexamethasone in Refractory or Relapsed and Refractory Multiple Myeloma Patients"]
["Oncology","Sarclisa \n(anti-CD38 mAb)","\nPhase 3\n","NCT04751877","Multicenter Open Label Phase 3 Study of Isatuximab Plus Lenalidomide and\nDexamethasone With/Without Bortezomib in the Treatment of Newly Diagnosed Non Frail Transplant Ineligible Multiple Myeloma Elderly Patients (# 65; < 80 Years)."]
["Oncology","Sarclisa \n(anti-CD38 mAb)","\n• Phase 1\n• Phase 2\n","NCT04643002","Isatuximab in Combination With Novel Agents in RRMM - Master Protocol"]
["Oncology","Sarclisa \n(anti-CD38 mAb)","\nPhase 2\n","NCT05704049","A Study to Investigate Subcutaneous Isatuximab in Combination With Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma"]
["Oncology","Sarclisa \n(anti-CD38 mAb)","\nPhase 3\n","NCT05405166","SC Versus IV Isatuximab in Combination With Pomalidomide and Dexamethasone in RRMM"]
["Oncology","Rezurock \n(ROCK2 inhibitor)","\nPhase 3\n","NCT06143891","A Study to Test an Oral Medicine, Belumosudil, in Combination With Corticosteroids in Participants at Least 12 Years of Age With Newly Diagnosed Chronic Graft Versus Host Disease."]
["Oncology","SAR443579 \n(Trifunctional anti-CD123 NK Cell engager) ","\n• Phase 1\n• Phase 2\n","NCT05086315","First-in-human Study of SAR443579 Infusion in Male and Female Children and Adult Participants With Relapsed or Refractory Acute Myeloid Leukemia (R/R\nAML), B-cell Acute Lymphoblastic Leukemia (B-ALL), High Risk-myelodysplasia (HR- MDS), or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)"]
["Oncology","SAR444881 \n(anti-ILT2 mAb)","\n• Phase 1\n• Phase 2\n","NCT04717375","Study of SAR444881 Administered Alone and in Combination With Other Therapeutics in Participants With Advanced Solid Tumors"]
["Oncology","SAR445953 \n(anti-CEACAM5-Topo1 ADC)","\nPhase 1\n","NCT06131840","A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors"]
["Oncology","SAR445514 \n(Trifunctional anti-BCMA NK Cell engager)","\n• Phase 1\n• Phase 2\n","NCT05839626","A Study to Investigate Safety and Efficacy With SAR445514 in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) and Relapsed/Refractory Light- chain Amyloidosis (RRLCA)"]
["Oncology","SAR445877 \n(anti-PD1/IL15 fusion protein)","\n• Phase 1\n• Phase 2\n","NCT05584670","A First-in-human, Dose Escalation and Dose Expansion Study of SAR445877 in Adult Participants With Advanced Solid Tumors"]
["Oncology","SAR444200 \n(anti-GPC3/TCR Nanobody VHH)","\n• Phase 1\n• Phase 2\n","NCT05450562","Dose Escalation and Expansion Study of SAR444200-based Regimen in Adult\nParticipants With Advanced Solid Tumors"]
["Oncology","pegenzileukin \n(Non-alpha IL2 Synthorin molecule)","\n• Phase 1\n• Phase 2\n","NCT04009681","A Study Evaluating Safety and Therapeutic Activity of THOR-707 in Adult Subjects With Advanced or Metastatic Solid Tumors (THOR-707-101) (HAMMER)"]
["Oncology","pegenzileukin \n(Non-alpha IL2 Synthorin molecule)","Phase 2","NCT05179603","A Study of SAR444245 With or Without Other Anticancer Therapies for the Treatment of Adults and Adolescents With Relapsed or Refractory B Cell Lymphoma (Master Protocol) [Pegathor Lymphoma 205]"]
["Oncology","pegenzileukin \n(Non-alpha IL2 Synthorin molecule)","Phase 2","NCT05104567","A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With\nGastrointestinal Cancer (Master Protocol) (Pegathor Gastrointestinal 203)"]
["Oncology","pegenzileukin \n(Non-alpha IL2 Synthorin molecule)","Phase 2","NCT05061420","A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With HNSCC (Master Protocol) (Pegathor Head and Neck 204)"]
["Oncology","pegenzileukin \n(Non-alpha IL2 Synthorin molecule)","Phase 2","NCT04914897","A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With Lung Cancer or Mesothelioma (Pegathor Lung 202)"]
["Oncology","pegenzileukin \n(Non-alpha IL2 Synthorin molecule)","\n• Phase 1\n• Phase 2\n","NCT04913220","A Study of SAR444245 Combined With Cemiplimab for the Treatment of\nParticipants With Various Advanced Skin Cancers (Pegathor Skin 201)"]
["Vaccines","SP0282 \n(Extraintestinal Pathogenic E. Coli Vaccine ExPEC9V)","\nPhase 3\n","NCT04899336","A Study of Vaccination With 9-valent Extraintestinal Pathogenic Escherichia Coli Vaccine (ExPEC9V) in the Prevention of Invasive Extraintestinal Pathogenic\nEscherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years"]
["Vaccines","SP0256 \n(mRNA RSV Combination Vaccine)","\n• Phase 1\n• Phase 2\n","NCT06134648","Study of a Respiratory Syncytial Virus/ Human Metapneumovirus Vaccine Candidate"]
["Vaccines","SP0256 \n(mRNA RSV Combination Vaccine)","Phase 1","NCT06237296","Study of the Safety and Immune Response of an Investigational mRNA Vaccine for the Prevention of Respiratory Syncytial Virus and/​or Human Metapneumovirus in Participants Aged 18 to 49 Years and 60 Years and Older"]
["Vaccines","SP0256 \n(mRNA RSV Vaccine)","\n• Phase 1\n• Phase 2\n","NCT05639894","Study of a Respiratory Syncytial Virus mRNA Candidate With 2 Different Lipid Nanoparticle-based Formulations in Adults Aged 18 to 50 Years and 60 Years and Older"]
["Vaccines","MenQuadfi \n(Meningococcal ACYW conjugate vaccine)","\nPhase 3\n","NCT04143061","Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Healthy Adults, Adolescents, Children, and Toddlers in India and Healthy Adolescents and Children in the Republic of South Africa"]
["Vaccines","MenQuadfi \n(Meningococcal ACYW conjugate vaccine)","\nPhase 3\n","NCT03691610","Immunogenicity and Safety Study of a Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers"]
["Vaccines","MenQuadfi \n(Meningococcal ACYW conjugate vaccine)","\nPhase 3\n","NCT03547271","Immunogenicity and Safety Study of a Quadrivalent Meningococcal Conjugate Vaccine When Co-administered With Routine Pediatric Vaccines in Healthy Infants and Toddlers in Europe"]
["Vaccines","MenQuadfi \n(Meningococcal ACYW conjugate vaccine)","\nPhase 3\n","NCT03537508","Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers in the US"]
["Vaccines","MenQuadfi \n(Meningococcal ACYW conjugate vaccine)","\nPhase 3\n","NCT05794230","Study of a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) Given With Routine Pediatric Vaccines in Healthy Infants and Toddlers in India and the Republic of South Africa"]
["Vaccines","MenQuadfi \n(Meningococcal ACYW conjugate vaccine)","\nPhase 3\n","NCT04936685","Study on an Investigational Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) Administered as a 5- and/or 10-year Booster Doses in Children and Adolescents Vaccinated 5 or 10 Years Earlier as Toddlers"]
["Vaccines","MenQuadfi \n(Meningococcal ACYW conjugate vaccine)","Phase 3","NCT06228586","Study on a MenACYW Conjugate Vaccine Administered as a Single Dose in Participants Aged 12 Months and Older in Vietnam"]
["Vaccines","MenQuadfi \n(Meningococcal ACYW conjugate vaccine)","Phase 3","NCT06284915","Study on Immunogenicity and Safety of a Meningococcal ACYW Conjugate Vaccine in Healthy Infants and Toddlers"]
["Vaccines","SP0087 \n(Purified vero rabies vaccine)","\nPhase 3\n","NCT04127786","Study of Purified Vero Rabies Vaccine Compared With Two Reference Rabies Vaccines, Given in a Pre-exposure Regimen to Children and Adults and as Single Booster Dose to a Subset of Adults"]
["Vaccines","SP0125 \n(Live-Attenuated RSV Vaccine)","Phase 3","NCT06252285","Efficacy, Immunogenicity, and Safety Study of a Respiratory Syncytial Virus Vaccine in Infants and Toddlers (PEARL)"]
["Vaccines","SP0230 \n(Pentavalent Meningococcal ABCYW conjugate vaccine)","\n• Phase 1\n• Phase 2\n","NCT06128733","Study of an Investigational Pentavalent Meningococcal ABCYW Vaccine in Adults and Adolescents"]
["Vaccines","SP0273 \n(mRNA QIV Vaccine)","\n• Phase 1\n• Phase 2\n","NCT05553301","Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5407 in Adult Participants18 Years of Age and Older"]
["Vaccines","SP0273 \n(mRNA QIV Vaccine)","\nPhase 1\n","NCT05829356","Substudy 01 - Safety and Immunogenicity of One Monovalent Modified mRNA Vaccine Encoding Influenza Hemagglutinin With LNP, in Adult Participants Aged 18 to 49 Years and 60 Years and Above"]
["Vaccines","SP0125 \n(Live-Attenuated RSV Vaccine)","\n• Phase 1\n• Phase 2\n","NCT05687279","Study on a Live-attenuated Respiratory Syncytial Virus Vaccine for Assessment of Safety, Transmissibility, and Genetic\nStability of the Vaccine Virus Among Close Contacts in Infants and Toddlers 6 to < 24 Months of Age in Puerto Rico (USA)"]
["Vaccines","SP0218 \n(Yellow fever vaccine)","\nPhase 2\n","NCT04942210","Study on an Investigational Yellow Fever Vaccine Compared With YF-VAX in Adults in the USA"]
["Vaccines","SP0230 \n(Multicomponent Meningococcal vaccine)","\n• Phase 1\n• Phase 2\n","NCT04825223","Study of a Novel Multicomponent Meningococcal Group B Vaccine When Given Alone or With Other Licensed Vaccines in Adults, Adolescents, Toddlers and Infants"]